|Awarded On||August 17, 2016|
|Title||DNA-Protein Crosslink Repair Pathways and Cancer Therapy|
|Award Mechanism||Multi-Investigator Research Awards (Version 2)|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Junjie Chen|
|Cancer Sites||All Sites|
Human cells have to cope with DNA damage that occurs naturally or is induced by exogenous sources like sunlight exposure. There are many types of DNA damage, one of which is DNA-protein crosslinks (DPCs; proteins trapped on DNA). DPCs are one of the most toxic types of damage in the cell, since they act as roadblock and prevent any event that takes place on DNA. It is now known that several commonly used chemotheraputic agents kill tumor cells by inducing abundant DPC lesions. This list includes irinotecan, topotecan, camptothecin, etoposide (VP-16), doxorubicin, daunorubicin and anthracycline. These drugs have been approved by FDA for the treatment of ovarian, lung, colon, and many other ty...